[Adults] {Spam? 4.04} Nuvilex, Inc. One Step Nearer to Going After Eli Lilly’s $1.4 Bil_lion Each Year in Advanced, Inoperable Pancreas Can_cer Therapies

[Biomed Info]

Nuvilex, Inc. One Hurdle Closer to Opposing Eli Lilly’s $1.4 Bil_lion
Yearly in Advanced, Inoperable Pancreas Can_cer Treatment

Eli Lilly’s (NYSE: LLY) drug, Gemzar, the typical single dr_ug for
pancreas can_cer recipients equals to approximately $1.4-bi_llion yearly to
Eli Lilly.  There is a lot at stake in the future of Nuvilex, Inc.’s
(OTCQB: NVLX) Phase III clinical tests – for Eli Lilly, for Nuvilex and
for can_cer patients who are searching for a improved option than the
present single agent “gold standard.”

Everyone has to envisage with the statistics Nuvilex has previously put on
the table in two independent Phase II tests… that this is a direct
matchup that Nuvilex deeply awaits while Eli Lilly might be worried about
the end results.  Nuvilex has generated superior outcomes when compared to
past statistics for Gemzar, and now the company is set to use real time,
head to head data to demonstrate its treatment is better than Eli
Lilly’s.

If the outcomes att-ained with Nuvilex’s therapy are statistically
superior to those found with Gemzar, the firm’s therapy could replace
Gemzar’s 17-year rule as the single agent “gold standard” for the
treatment of this horrific dis_ease.  This would obviously be good news for
customers afflicted with the di_sease, and it would be huge news for
Nuvilex’s shareholders.

5847 San Felipe, 17th Fl., Houston, Tex 77057 U.S.A.

The use of research materials circulated by the auth.or is done at your own
risk. You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
distribution of these materials. You should presume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could end
in our trading securities at any time before, during, and/or after the
disbursement of this commercial report.

Unsubscribe me from this list
http://info.apropositodjiboutianap.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=2169
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/adults/attachments/20130806/2edb1af9/attachment.html>